Disease relevance of Herpes Genitalis

• Two hundred fifty patients were entered into a multicenter trial to evaluate the efficacy and toxicity of orally administered acyclovir for treatment of recurrent genital herpes [1].
• Effect of acyclovir treatment of primary genital herpes on the antibody response to herpes simplex virus [2].
• Thirty-one patients with first episodes of genital herpes were randomized in a double-blind fashion to intravenous treatment with saline placebo or acyclovir, 5 mg/kg body weight at 8-hour intervals, for 5 days [3].
• The antiviral activity of recombinant human macrophage CSF (M-CSF) against genital herpes simplex virus type-2 (HSV-2) infection in guinea pigs was investigated [4].
• There was no decline in the high seroprevalence associated with a discharge diagnosis of gonorrhea (58%) or any genital ulcer disease (GUD; e.g., primary or secondary syphilis, chancroid or genital herpes, 52%) [5].

Psychiatry related information on Herpes Genitalis

• Improving a patient's problem-solving skills, and long-term aciclovir therapy should form an integral part of the long-term management of recurrent genital herpes [6].

High impact information on Herpes Genitalis

• RESULTS: HSV was isolated from the genital mucosa in 38 of the 53 HSV-2-seropositive subjects (72 percent) who reported no history of genital herpes, and HSV DNA was detected by the polymerase-chain-reaction assay in cultures prepared from genital mucosal swabs in 6 additional subjects [7].
• Brief report: recurrent acyclovir-resistant genital herpes in an immunocompetent patient [8].
• Nonoxynol 9 cream for genital herpes simplex [9].
• Carbocyclic arabinofuranosyladenine (cyclaradine): efficacy against genital herpes in guinea pigs [10].
• Oral famciclovir for the suppression of recurrent genital herpes: a randomized controlled trial. Collaborative Famciclovir Genital Herpes Research Group [11].

Chemical compound and disease context of Herpes Genitalis

• Famciclovir for genital herpes [12].
• The use of 2-deoxy-D-glucose for genital herpes [13].
• Topical idoxuridine in the treatment of genital herpes [14].
• Ineffectiveness of topical idoxuridine in dimethyl sulfoxide for therapy for genital herpes [15].
• Thirty-six women with genital herpes infections (proved by virological or cytological means) were treated in a double-blind placebo-controlled study with the glucose analogue 2-deoxy-D-glucose for a three-week period [16].

Biological context of Herpes Genitalis

• Topical acyclovir shortens the duration of viral shedding and accelerates healing of some genital herpes simplex virus infections [17].
• We conclude that oral acyclovir suppresses genital herpes in patients with frequent recurrences, but the potential for problems with drug resistance and the long-term safety need to be more fully explored [18].
• These data suggest that neural pathways are important in the pathogenesis of genital herpes and that virus-coded thymidine kinase may influence virulence but is not required for latency [19].
• These data suggest that acyclovir may be a promising drug for altering the severity of clinical genital herpes in humans during acute infection and reducing the incidence of viral latency following primary infection [20].
• CONCLUSION: Our study suggests that asymptomatic shedding of virus is not prevented by use of oral acyclovir during late gestation in proven recurrent genital herpes even though plasma acyclovir levels were within the normal range [21].

Anatomical context of Herpes Genitalis

• Isopentenyl pyrophosphate-reactive Vgamma9Vdelta 2 T helper 1-like cells are the major gammadelta T cell subset recovered from lesions of patients with genital herpes [22].
• Cytopenia, elevated C-reactive protein, ferritin, soluble interleukin-2 receptor, and interleukin-6 with high-grade fever were observed following genital herpes infection, and the existence of hemophagocytes in bone marrow confirmed the diagnosis of hemophagocytic lymphohistiocytosis [23].
• We describe a 28-year-old HIV-infected woman with AIDS, defined by cerebral toxoplasmosis and a CD4-count of less than 10 x 10(6) cells/I, who, after several eruptions of genital herpes and typical dermatomal herpes zoster, all successfully treated with acyclovir, developed chronic cutaneous ulcerating lesions on a finger and on the tibia [24].

Gene context of Herpes Genitalis

• Neurokinin 1 receptor signaling affects the local innate immune defense against genital herpes virus infection [25].
• Interleukin-15 and natural killer and NKT cells play a critical role in innate protection against genital herpes simplex virus type 2 infection [26].
• Dysregulated expression of IFN-gamma and IL-10 and impaired IFN-gamma-mediated responses at different disease stages in patients with genital herpes simplex virus-2 infection [27].
• The patients with genital herpes showed a significant reduction in the ability to produce IFN-alpha and a slight decrease in the ability to produce IFN-gamma [28].
• Protective immunity to genital herpes simplex [correction of simpex] virus type 2 infection is mediated by T-bet [29].

Analytical, diagnostic and therapeutic context of Herpes Genitalis

• A randomized, double-blind study of valaciclovir for suppression of recurrent genital herpes was conducted among 1479 immunocompetent patients [30].
• Valaciclovir represents and advance in antiherpes drug therapy and is a useful treatment option for patients with herpes zoster or genital herpes [31].
• STUDY DESIGN: Four-hundred thirteen sera from 113 patients with recently acquired genital herpes were tested by HerpeSelect ELISAs and Western blot (WB) [32].
• Performance of the focus and Kalon enzyme-linked immunosorbent assays for antibodies to herpes simplex virus type 2 glycoprotein G in culture-documented cases of genital herpes [33].
• METHODS: We conducted a retrospective study of virologically proven first-episode genital herpes diagnosed in the Department of Genitourinary Medicine in Edinburgh between 1989 and 2002 [34].

References